Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND) (DIAMOND)
The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:
- What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?
- Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Haizeng Zhang, Doctorate
- Phone Number: +8613511003686
- Email: haizengzhang@163.com
Study Locations
-
-
-
Beijing, China, 100021
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Haizeng Zhang, Doctorate
- Phone Number: +8613511003686
- Email: haizengzhang@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged between 18 and 80 years
- Pathologically confirmed adenocarcinoma of the colon or rectum
- Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol
- No distant metastasis or distant metastasis within 6 months after surgery
- No history of other malignant tumors or severe systemic diseases
- No immune diseases or inflammatory bowel diseases
- Non-emergency surgery
- With complete clinicopathological and follow-up data
Exclusion Criteria:
- Pathologically confirmed benign tumors or non-adenocarcinoma malignancies
- Underwent local excision or palliative resection
- Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol
- With distant metastasis or distant metastasis within 6 months after surgery
- Dual or multiple primary colorectal cancers or concurrent other malignant tumors
- Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease
- Underwent emergency surgery
- Had incomplete clinicopathological or follow-up data
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Colorectal Cancer Patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The spatial distribution of metastatic lymph nodes
Time Frame: From enrollment to 14 days after surgery (at the completion of postoperative pathological examination)
|
From enrollment to 14 days after surgery (at the completion of postoperative pathological examination)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease-free survival
Time Frame: From date of surgery until the date of first documented local recurrence, distant metastasis, or date of death from any cause, whichever came first, assessed up to 60 months
|
From date of surgery until the date of first documented local recurrence, distant metastasis, or date of death from any cause, whichever came first, assessed up to 60 months
|
|
Overall survival
Time Frame: From date of surgery until the date of death from any cause, whichever came first, assessed up to 60 months
|
From date of surgery until the date of death from any cause, whichever came first, assessed up to 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Haizeng Zhang, Doctorate, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colonic Diseases
- Neoplastic Processes
- Neoplasm Metastasis
- Pathological Conditions, Signs and Symptoms
- Rectal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Lymphatic Metastasis
Other Study ID Numbers
Other Study ID Numbers
- 25/631-5577
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.